. 2017 Nov 27;73(3):596–606. doi: 10.1093/jac/dkx430

Table 3.

Clinical trial design including number of treated and cured patients (sorted by descending number of arms and by treatment in alphabetical order)

First author, year	Design (no. of trials)	Arms	ABZ	AGA	CQ	FZD	MBZ	MEN	MTZ	NTZ	OLZ	OZN	PLA	PPS	PRM	PZQ	QC	SAU	SCZ	TNZ
Chan del Pino, 1999	ABZ/FZD/MTZ/SCZ/TNZ (1)	5	11/17			14/15			13/17										11/15	13/15
Bassily, 1970	FZD/MTZ/PLA/QC (1)	4				16/20			19/20				0/20				20/20
Escobedo, 2003a	ABZ/CQ/TNZ (1)	3	37/60		43/50															50/55
Speich, 2013	ABZ/NTZ/PLA (1)	3	15/25							12/21			13/25
Kalayci, 1995	FZD/MBZ/MTZ (1)	3				12/15	11/15		14/15
Chacon, 1991	FZD/MTZ/SCZ (1)	3				19/20			18/20										12/17
Bulut, 1996	MBZ/MTZ/OZN (1)	3					12/34		13/15			10/11
Imani, 2004	MBZ/MTZ/PZQ (1)	3					15/30		28/30							17/30
Nunez, 2004	MTZ/PPS/PRM (1)	3							71/89					80/108	54/59
Alizadeh, 2006	ABZ/MTZ (10)	2	54/60						46/60
Cañete, 2012			62/75						64/75
Dutta, 1994			73/75						73/75
Hall, 1993a			112/144						77/78
Hall, 1993b			122/141						63/63
Karabay, 2004			27/33						29/34
Misra, 1995			28/32						29/32
Rodriguez-Garcia, 1996			21/27						16/22
Romero-Cabello, 1995			47/50						49/50
Yereli, 2004			47/52						49/55
Bances-Garcia, 2013	ABZ/NTZ (1)	2	40/49							43/49
Mendoza, 2003	ABZ/TNZ (3)	2	17/49																	31/43
Pengsaa, 1999			31/68																	49/63
Pengsaa, 2002			13/26																	25/27
Sahib, 2014	AGA/MTZ (1)	2		14/14					14/14
Canete, 2010	CQ/MTZ (1)	2			52/61				45/61
Garg, 1972	FZD/MTZ (3)	2				38/40			38/40
Nair, 1979						16/20			16/19
Quiros-Buelna, 1989						34/50			43/50
Al-Waili, 1992	MBZ/MTZ (4)	2					21/23		18/21
Gascon, 1989							2/14		8/9
Gascon, 1990							1/8		10/11
Sadjjadi, 2001							43/50		45/50
Davila-Gutierrez, 2002	MBZ/NTZ (2)	2					11/19			18/32
Rodriguez-Garcia, 1999	MBZ/NTZ (2)	2					33/41			32/41
Canete, 2006a	MBZ/QC (1)	2					48/61										51/61
Almirall, 2011	MBZ/SCZ (2)	2					55/64												56/62
Escobedo, 2003b	MBZ/SCZ (2)	2					57/73												58/73
Canete, 2006b	MBZ/TNZ (1)	2					39/61													50/61
Teles, 2011	MEN/SCZ (1)	2						22/50											42/50
Ortiz, 2001	MTZ/NTZ (1)	2							41/55	39/55
Leite, 1976	MTZ/OZN (2)	2							12/15			13/15
Oren, 1991	MTZ/OZN (2)	2							37/37			35/38
Kavousi, 1979	MTZ/QC (1)	2							75/80								69/80
Cimerman, 1988	MTZ/SCZ (2)	2							52/60										57/62
Rastegar-Lari, 1996	MTZ/SCZ (2)	2							24/25										27/27
Fallah, 2007	MTZ/TNZ (7)	2							43/64											37/42
Gazder, 1977									19/50											40/50
Kyronseppa, 1981									19/25											22/25
Nigam, 1991									19/35											39/40
Perez-Choliz, 1989									12/27											23/25
Speelman, 1985a									9/17											16/18
Speelman, 1985b									14/17											15/18
Rossignol, 2001	NTZ/PLA (1)	2								12/17			0/19
Escobedo, 2008	NTZ/TNZ (1)	2								58/85										57/81
Amoroto, 2002	OLZ/OZN (1)	2									63/112	67/112
Begaydarova, 2014	OZN/SAU (1)	2										53/125						107/125
Jokipii, 1982	OZN/TNZ (1)	2										45/50								45/50
Miyares, 1988	PPS/TNZ (1)	2												22/45						17/45
Cimerman, 1997	SCZ/TNZ (2)	2																	116/129	120/138
Cimerman, 1999	SCZ/TNZ (2)	2																	144/160	142/161

ABZ, albendazole; AGA, Anethum graveolens; CQ, chloroquine; FZD, furazolidone; MBZ, mebendazole; MEN, Mentha crispa; MTZ, metronidazole; NTZ, nitazoxanide; OLZ, oleozon; OZN, ornidazole; PLA, placebo; PPS, propolis; PRM, paromomycin; PZQ, praziquantel; QC, quinacrine; SAU, sausalin; SCZ, secnidazole; TNZ, tinidazole.